Research Analysts’ Recent Ratings Updates for DURECT (DRRX)

DURECT (NASDAQ: DRRX) has recently received a number of price target changes and ratings updates:

• 11/27/2024 – DURECT is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 11/19/2024 – DURECT is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 11/14/2024 – DURECT had its “neutral” rating reaffirmed by analysts at HC Wainwright.
• 11/11/2024 – DURECT is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 11/3/2024 – DURECT is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 10/26/2024 – DURECT is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 10/18/2024 – DURECT is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 10/10/2024 – DURECT is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.

DURECT Trading Up 4.5 %

Shares of NASDAQ:DRRX traded up $0.04 on Monday, reaching $0.92. The company had a trading volume of 57,337 shares, compared to its average volume of 133,527. DURECT Co. has a 52-week low of $0.48 and a 52-week high of $1.88. The firm’s 50 day simple moving average is $1.24 and its 200-day simple moving average is $1.36. The firm has a market capitalization of $28.56 million, a PE ratio of -1.51 and a beta of 1.13.

Institutional Trading of DURECT

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Richmond Brothers Inc. lifted its holdings in shares of DURECT by 39.5% in the 2nd quarter. Richmond Brothers Inc. now owns 1,072,014 shares of the specialty pharmaceutical company’s stock valued at $1,383,000 after buying an additional 303,670 shares during the period. Geode Capital Management LLC lifted its holdings in shares of DURECT by 4.8% in the 3rd quarter. Geode Capital Management LLC now owns 319,905 shares of the specialty pharmaceutical company’s stock valued at $429,000 after buying an additional 14,658 shares during the period. Accredited Investors Inc. purchased a new position in shares of DURECT in the 2nd quarter valued at about $113,000. Finally, International Assets Investment Management LLC increased its stake in shares of DURECT by 41.3% in the 2nd quarter. International Assets Investment Management LLC now owns 21,550 shares of the specialty pharmaceutical company’s stock valued at $28,000 after purchasing an additional 6,300 shares in the last quarter. Institutional investors and hedge funds own 28.03% of the company’s stock.

DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis.